Body Handbook კატალოგი პროფილი რეიტინგი
სკრინინგი BODY HANDBOOK
სკრინინგი · §135
MTHFR Testing
MTHFR is a real gene, and the wellness test for it is one thing medicine has actually settled: skip it. Around half of everyone carries the variant it reports, and every relevant society, from geneticists to obstetricians, says don't order it. What the $99 buys is a label, a lifelong supplement habit, and, for women planning a pregnancy, a panic loop with no clinical basis. The reason it doesn't matter is clean: your folate plan is identical whether you carry the variant or not.
აარიდე · ერთხელ მტკიცებულება ძლიერი თავი სკრინინგი

The gene is real; the "mutation" is common. MTHFR codes for one enzyme in your folate cycle. Two copies of the slow variant run that enzyme at about 30% speed in a test tube 1. But one in three people of European descent carries a slow copy and one in ten carries two 2. "Mutation" is a marketing word when 40% of your friends have it. In real bodies the pathway has spare capacity, and once countries fortified flour, blood markers in the slow group dropped back to normal 3.

Every use it's sold for fails the same test. Heart disease: three trials gave at-risk patients B-vitamins, dropped their homocysteine about a quarter, and heart attacks and strokes didn't move 4, 5. A Cochrane review pooling every trial agrees 6. Blood clots: the blood-doctor list of tests to stop ordering names MTHFR by name 7. Miscarriage: it's left out of both the OB/Gyn and fertility workups 8, 9.

The one real link changes nothing. The slow variant does nudge up neural-tube-defect risk in pregnancy. But the protective dose of folic acid is the same for carriers and everyone else 10, 3. If the result never alters the advice, the test isn't worth running.

Your folate plan doesn't need your genotype.

Saying no saves you the arc, not the $99. A positive result — and roughly half of takers get one — usually leads to a forum, then a first order of methylfolate and methyl-B12, then a stack that grows to around $1,500 a year of supplements with no trial behind them. For women planning a pregnancy it's worse: a past miscarriage gets reread as the gene's fault, and the obstetrician's ordinary 400-mcg advice starts to feel insufficient 11. The clinical reality doesn't change. The story you now carry does.

The fine print — when to skip it, and what people get wrong

"Carriers can't use folic acid." Backwards. A different enzyme handles folic acid; carriers process it normally 12. At the prenatal dose, methylfolate and folic acid raise red-cell folate the same, and methylfolate costs about four times more 13.

One edge caveat: folic acid above 1 mg a day, well past the prenatal dose, can mask early B12 deficiency in older adults. An argument against megadosing, not against the normal 400 mcg.

References
  1. 1Frosst P, Blom HJ, Milos R et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. link
  2. 2Wilcken B, Bamforth F, Li Z et al. (2003). Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. Journal of Medical Genetics. link
  3. 3Crider KS, Qi YP, Devine O et al. (2018). Modeling the impact of folic acid fortification and supplementation on red blood cell folate concentrations and predicted neural tube defect risk. Birth Defects Research. link
  4. 4Lonn E, Yusuf S, Arnold MJ et al. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease (HOPE-2). New England Journal of Medicine. link
  5. 5Bønaa KH, Njølstad I, Ueland PM et al. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction (NORVIT). New England Journal of Medicine. link
  6. 6Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M (2017). Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews. link
  7. 7ASH (2013). Don't test for MTHFR polymorphisms for the evaluation of patients with thrombosis. Choosing Wisely. link
  8. 8ACOG (2018). ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. link
  9. 9ASRM Practice Committee (2012). Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertility and Sterility. link
  10. 10MRC Vitamin Study Research Group (1991). Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. The Lancet. link
  11. 11Levin BL, Varga E (2016). MTHFR: Addressing genetic counseling dilemmas using evidence-based literature. Journal of Genetic Counseling. link
  12. 12Stover PJ, Field MS (2011). Trafficking of intracellular folates. Advances in Nutrition. link
  13. 13Pietrzik K, Bailey L, Shane B (2010). Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. link
დაკავშირებული სახელმძღვანელოში (5)
დაკავშირებული
  • — You don't need an MTHFR test to decide on folate; ordinary folic acid works fine for nearly everyone, including those with the variant.
  • — Plenty of genetic tests rewrite your care; MTHFR is the one nearly every specialty society tells you to skip.
  • — Like IgG food panels, MTHFR testing is a high-marketing, low-value test the specialty bodies recommend against.
  • — MTHFR is the over-hyped cousin of real pharmacogenomics — heavily marketed, rarely changing what anyone should actually do.
  • — The supplement cascade a positive result triggers usually includes methyl-B12 too — worth knowing what B12 actually does before you start.
·
135